DBV Technologies to Present Data on VIASKIN® Peanut at AAAAI 2026
DBV Technologies announces that it will present additional data from the phase 3 VITESSE study on the VIASKIN® Peanut patch in children aged 4 to 7 at the 2026 annual meeting of the American Academy of Allergy, Asthma, and Immunology. The company will also host a product forum focused on the potential of epicutaneous immunotherapy (EPIT) in treating food allergies.
DBV Technologies will deliver an oral presentation titled 'VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age' at the 2026 AAAAI annual meeting, which will be held in Philadelphia, Pennsylvania, from February 27 to March 2, 2026. The company will also organize a product forum featuring a panel of allergists to discuss the potential of EPIT to re-educate the immune system in the case of food allergies, examine the impact of early intervention in children allergic to peanuts, and analyze how new therapeutic options enable a more proactive approach to managing this allergy.
Exhibition Details
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
DBV Technologies will be located at booth #1527 in the exhibition hall of the AAAAI, where attendees can receive information about epicutaneous immunotherapy and the VIASKIN® Peanut patch. The advanced-stage biopharmaceutical company focuses on developing treatment options for food allergies and other immune conditions. DBV Technologies is currently studying the use of its proprietary VIASKIN® patch technology to treat food allergies, with ongoing programs in young children aged 1 to 3 years and children aged 4 to 7 years who are allergic to peanuts.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
